Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | USP2 | O75604 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.39 |
| ▸ | ATM | Q13315 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.39 |
| ▸ | RELA | Q04206 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1372192 | 0.86 | TSHR (0.41) | HPGDRAB9ASMN1; SMN2NPC1TSHR | |
| SCHEMBL9988096 | 0.85 | MCL1 (0.37) | HPGDRAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL1371322 | 0.79 | TSHR (0.39) | HPGDRAB9ASMN1; SMN2NPC1TSHR | |
| SCHEMBL31337248 | 0.77 | HPGD (0.52) | HPGDRAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL758202 | 0.77 | HPGD (0.52) | HPGDRAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL29103081 | 0.74 | HPGD (0.50) | HPGDRAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL2196851 | 0.74 | BCL2L1 (0.54) | HPGDMAPTMEN1KMT2AALOX15 | |
| SCHEMBL8129047 | 0.73 | ACHE (0.41) | HPGDRAB9ASMN1; SMN2MAPTNPC1 | |
| SCHEMBL75115 | 0.72 | — | — | |
| SCHEMBL2373481 | 0.71 | ALDH1A1 (0.44) | HPGDRAB9ASMN1; SMN2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE39708-E1 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1102753-B1 | PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2007-02-28 | — | — | EP | disclosed |
| US-6869969-B2 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2005-03-22 | — | — | US | disclosed |
| US-6743815-B2 | OSTEOPOROSIS; ENDOMETRIOSIS; ALZHEIMER'S DISEASE | CHIRON CORPORATION | 2004-06-01 | — | — | US | disclosed |
| US-20040102498-A1 | Cycloalkylene compounds with substituents as anticancer agents, atheriosclerosis and estrogen receptors | CHIRON CORPORATION | 2004-05-27 | — | — | US | disclosed |
| US-6727273-B2 | THERAPY FOR OSTEOPOROSIS, ANTICANCER AGENTS | CHIRON CORPORATION | 2004-04-27 | — | — | US | disclosed |
| US-20040077701-A1 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2004-04-22 | — | — | US | disclosed |
| US-20040034081-A9 | ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION | 2004-02-19 | — | — | US | disclosed |
| US-20030065012-A1 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2003-04-03 | — | — | US | disclosed |
| US-20020111374-A1 | Estrogen receptor modulators | CHIRON CORPORATION | 2002-08-15 | — | — | US | disclosed |
| US-6387920-B2 | ISOXAZOLE COMPOUNDS; FOR TREATING ESTROGEN RECEPTOR-MEDIATED DISORDERS SUCH AS OSTEOPOROSIS, BREAST AND ENDOMETRIAL CANCERS, ATHEROSCLEROSIS, ALZHEIMER'S DISEASE | CHIRON CORPORATION | 2002-05-14 | — | — | US | disclosed |
| US-20010036956-A1 | Estrogen receptor modulators | HUEBNER VERENA D (US) | 2001-11-01 | — | — | US | disclosed |
| US-6291505-B1 | PYRAZOLE ESTROGEN RECEPTOR AGONIST AND ANTAGONIST | CHIRON CORPORATION | 2001-09-18 | — | — | US | disclosed |
| US-6262098-B1 | ISOXAZOLE ESTROGEN RECEPTOR AGONIST AND ANTAGONIST | CHIRON CORPORATION | 2001-07-17 | — | — | US | disclosed |
| EP-1102753-A2 | PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000007996-A2 | PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036956-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | HPGD 752/4885RAB9A 3093/4885SMN1; SMN2 4686/4885 |
| US-20040077701-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | HPGD 645/4885RAB9A 2665/4885SMN1; SMN2 4806/4885 |
| US-20030065012-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | HPGD 752/4885RAB9A 3093/4885SMN1; SMN2 4686/4885 |
| US-20040034081-A9 | ESTROGEN RECEPTOR MODULATORS | ESR1, ESR2, GPER1 | HPGD 645/4885RAB9A 2665/4885SMN1; SMN2 4806/4885 |
| US-20020111374-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | HPGD 645/4885RAB9A 2665/4885SMN1; SMN2 4806/4885 |
| US-20040102498-A1 | Cycloalkylene compounds with substituents as anticancer agents, atheriosclerosis and estrogen receptors | ESR2, GPER1, ESR1 | HPGD 918/4885RAB9A 3688/4885SMN1; SMN2 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.